RxDoctor Payments Data

Carl Gessner, MD

Gastroenterology · Greensboro, NCNPI 1871557116

Payments from drug & device makers

$1,309in general payments, 2019–2025

Across 63 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$152
  • Pentax Of America, Inc.$152
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$140
  • AbbVie$133
  • Dova Pharmaceuticals$120
  • Medtronic$115
  • plus $497 from 16 others

What the payments were for

  • Food & beverage$1,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,309 in reported general payments places this provider in the 40th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$68,890
Medicare patients
240
Services billed
813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab14$424,435
CreonLipase/Protease/Amylase25$91,975
XifaxanRifaximin12$44,496
Alosetron Hcl47$19,573
LinzessLinaclotide12$16,427
Mesalamine21$12,105
Pantoprazole Sodium287$4,522
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates62$4,118
Dexlansoprazole DrDexlansoprazole11$4,103
Omeprazole199$3,878
Mesalamine ErMesalamine18$3,508
Budesonide EcBudesonide20$3,328
Budesonide DrBudesonide30$2,951
Sucralfate26$2,766
Esomeprazole Magnesium54$2,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$40$424,43514 claims
AbbVieCreon, Linzess$133$108,40237 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$140$44,49612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →